A PHASE 1 TRIAL OF THE PARP INHIBITOR VELIPARIB IN COMBINATION WITH INTRAPERITONEAL FLOXURIDINE (FUDR) IN EPITHELIAL OVARIAN CANCER

被引：0
|
作者：
Hendrickson, A. Wahner [1 ]
Powell, M. [2 ]
Mutch, D. [2 ]
Tanner, E. [3 ]
Cliby, W. [4 ]
Swisher, E. [5 ]
Ralya, A. [6 ]
Reid, J. [7 ]
Burton, J. [1 ]
Wagner, J. [1 ]
Strand, C. [8 ]
Allred, J. [8 ]
Haluska, P. [9 ]
Erlichman, C. [1 ]
Ivy, S. P. [10 ]
Kaufmann, S. [1 ]
Karnitz, L. [11 ]
机构：
[1] Mayo Clin, Med Oncol, Rochester, MN USA
[2] Washington Univ, Gynecol Surg, St Louis, MO 63110 USA
[3] Johns Hopkins Univ, Gynecol & Obstet, Baltimore, MD USA
[4] Mayo Clin, Obstet & Gynecol, Rochester, MN USA
[5] Univ Washington, Obstet & Gynecol, Seattle, WA 98195 USA
[6] IQVIA, Clin PK PD, Overland Pk, KS USA
[7] Mayo Clin, Pharmacol, Rochester, MN USA
[8] Mayo Clin, Biomed Stat, Rochester, MN USA
[9] Merck & Co Inc, Oncol, Rahway, NJ 07065 USA
[10] NCI, NIH, Invest Drug Branch, CTEP, Bethesda, MD 20892 USA
[11] Mayo Clin, Oncol Res, Rochester, MN USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS8-0369
引用
下载
收藏
页码：460 / 461
页数：2
相关论文
共 50 条
  • [1] A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias
    Gojo, Ivana
    Beumer, Jan H.
    Pratz, Keith
    Ji, Jiuping
    Wang, Lihua
    Rudek, Michelle A.
    McDevitt, Michael A.
    Baer, Maria R.
    Blackford, Amanda
    Smith, B. Douglas
    Gore, Steven D.
    Carraway, Hetty E.
    Showel, Margaret M.
    Levis, Mark J.
    DeZern, Amy E.
    Gladstone, Douglas
    Jain, Tania
    Greer, Jackie
    Pouquet, Marie
    Ismail, Ali-Walbi
    Herman, James
    Poh, Weijie
    Karnitz, Larry
    Kaufmann, Scott H.
    Chen, Alice
    Karp, Judith E.
    BLOOD, 2015, 126 (23)
  • [2] Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).
    Wesolowski, Robert
    Zhao, Meng
    Geyer, Susan Michelle
    Lustberg, Maryam B.
    Mrozek, Ewa
    Layman, Rachel M.
    Macrae, Erin Macrae
    Zhang, Jun
    Hall, Nathan
    Schregel, Katharina
    Ottman, Susan
    Camp, Andrea
    Chalmers, Jeffrey J.
    Andreopoulou, Eleni
    Villalona-Calero, Miguel Angel
    Shapiro, Charles L.
    Knopp, Michael V.
    Greyer, Michael R.
    Ramaswamy, Bhuvaneswari
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
    Gojo, Ivana
    Beumer, Jan H.
    Pratz, Keith W.
    McDevitt, Michael A.
    Baer, Maria R.
    Blackford, Amanda L.
    Smith, B. Douglas
    Gore, Steven D.
    Carraway, Hetty E.
    Showel, Margaret M.
    Levis, Mark J.
    Dezern, Amy E.
    Gladstone, Douglas E.
    Ji, Jiuping Jay
    Wang, Lihua
    Kinders, Robert J.
    Pouquet, Marie
    Ali-Walbi, Ismail
    Rudek, Michelle A.
    Poh, Weijie
    Herman, James G.
    Karnitz, Larry M.
    Kaufmann, Scott H.
    Chen, Alice
    Karp, Judith E.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 697 - 706
  • [4] POPULATION PHARMACOKINETICS OF THE PARP INHIBITOR VELIPARIB IN WOMEN WITH OVARIAN CANCER.
    Boakye-Agyeman, F.
    Menefee, M.
    Erlichman, C.
    Northfelt, D.
    Kaufmann, S. H.
    Satele, D.
    Brundage, B. C.
    Reid, J. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S48 - S48
  • [5] Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
    Gray, Heidi J.
    Bell-McGuinn, Katherine
    Fleming, Gini F.
    Cristea, Mihaela
    Xiong, Hao
    Sullivan, Danielle
    Luo, Yan
    McKee, Mark D.
    Munasinghe, Wijith
    Martin, Lainie P.
    GYNECOLOGIC ONCOLOGY, 2018, 148 (03) : 507 - 514
  • [6] Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
    Secord, Angeles Alvarez
    O'Malley, David M.
    Sood, Anil K.
    Westin, Shannon N.
    Liu, Joyce F.
    GYNECOLOGIC ONCOLOGY, 2021, 162 (02) : 482 - 495
  • [7] Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
    Kumar Rajagopalan
    David Peereboom
    G. Thomas Budd
    Thomas Olencki
    Siva Murthy
    Paul Elson
    Denise McLain
    Ronald Bukowski
    Investigational New Drugs, 1998, 16 : 255 - 258
  • [8] Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
    Rajagopalan, K
    Peereboom, D
    Budd, GT
    Olencki, T
    Murthy, S
    Elson, P
    McLain, D
    Bukowski, R
    INVESTIGATIONAL NEW DRUGS, 1998, 16 (03) : 255 - 258
  • [9] The role of PARP inhibitor combination therapy in ovarian cancer
    Hockings, Helen
    Miller, Rowan E.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [10] A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
    Isakoff, S. J.
    Overmoyer, B.
    Tung, N. M.
    Gelman, R. S.
    Giranda, V. L.
    Bernhard, K. M.
    Habin, K. R.
    Ellisen, L. W.
    Winer, E. P.
    Goss, P. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345